Details

Autor(en) / Beteiligte

• Robichaux, Jacqulyne P.
• Elamin, Yasir Y.
• Vijayan, R.S.K.
• Nilsson, Monique B.
• Hu, Lemei
• He, Junqin
• Zhang, Fahao
• Pisegna, Marlese
• Poteete, Alissa
• Sun, Huiying
• Li, Shuai
• Chen, Ting
• Han, Han
• Negrao, Marcelo Vailati
• Ahnert, Jordi Rodon
• Diao, Lixia
• Wang, Jing
• Le, Xiuning
• Meric-Bernstam, Funda
• Routbort, Mark
• Roeck, Brent
• Yang, Zane
• Raymond, Victoria M.
• Lanman, Richard B.
• Frampton, Garrett M.
• Miller, Vincent A.
• Schrock, Alexa B.
• Albacker, Lee A.
• Wong, Kwok-kin
• Cross, Jason B.
• Heymach, John V.

Titel

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

Ist Teil von

• Cancer cell, 2019-10, Vol.36 (4), p.444-457.e7

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• We characterized the landscape and drug sensitivity of ERBB2 (HER2) mutations in cancers. In 11 datasets (n = 211,726), ERBB2 mutational hotspots varied across 25 tumor types. Common HER2 mutants yielded differential sensitivities to eleven EGFR/HER2 tyrosine kinase inhibitors (TKIs) in vitro, and molecular dynamics simulations revealed that mutants with a reduced drug-binding pocket volume were associated with decreased affinity for larger TKIs. Overall, poziotinib was the most potent HER2 mutant-selective TKI tested. Phase II clinical testing in ERBB2 exon 20-mutant non-small cell lung cancer resulted in a confirmed objective response rate of 42% in the first 12 evaluable patients. In pre-clinical models, poziotinib upregulated HER2 cell-surface expression and potentiated the activity of T-DM1, resulting in complete tumor regression with combination treatment. [Display omitted] •ERBB2 mutations occur in at least 25 tumor types with varying patterns of mutations•Mutation-induced changes in drug-binding pocket volume dictate drug sensitivity•Poziotinib inhibits mutant HER2, yielding a 42% response rate in NSCLC patients•Combination of poziotinib with T-DM1 potentiates antitumor activity of both agents Robichaux et al. show that ERBB2 mutation hotspots vary across human tumor types, which affect the volume of the HER2 TKI binding pocket and dictate drug sensitivity. Poziotinib is the most potent HER2 TKI among those tested. Moreover, poziotinib enhances T-DM1 efficacy by increasing the cell-surface HER2 level.